Bone and Mineral Metabolism Disorders News

An FDA advisory committee voted 9-4 in favor of the use of Xphozah as a monotherapy for controlling serum phosphorus levels in adults with chronic kidney disease on dialysis.

Due to a significant association between the urine to phosphate-to-creatinine ratio and mortality among individuals without chronic kidney disease, researchers suggest this may be a predictor for future adverse events in this population.

Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine, according to a company press release.

Compared with healthy controls, patients with chronic kidney disease or on hemodialysis have lower serum zinc levels more frequently than reported in daily clinical practice, according to data published in the Journal of Renal Nutrition.

WASHINGTON — In this Healio video exclusive, Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC, discusses the results of the DIAMOND trial of patiromer for the reduction of hyperkalemia in patients with HF with reduced ejection fraction.

BOSTON — Trial results show patiromer is effective in controlling hyperkalemia and helps to reduce the risk of using blood pressure medications in patients with chronic kidney disease and heart failure.

WASHINGTON — Patiromer, a novel potassium binder, was associated with a reduction in hyperkalemia in patients with HF with reduced ejection fraction, enabling an increase in adherence to optimal medical therapy, researchers reported.

Among patients with nephrolithiasis, using smart water bottles to remind them to hydrate and record water intake can increase urine volume, according to data published in the Journal of Renal Nutrition.

Low-dose sevelamer in combination with a calcium-based phosphorus binder may be used in resource-constrained countries as a second-line therapy for patients with hyperphosphatemia to minimize calcium loading.

In addition to being male and of older age, being Black or Hispanic can increase a patient’s risk for hyperkalemia recurrence within 1 year of a hyperkalemia event, according to data presented at ASN Kidney Week.